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Diabetic retinopathy is a leading cause of vision loss. The primary clinical hallmarks are vascular changes that appear to contribute
to the loss of sight. In a number of neurodegenerative disorders there is an appreciation that increased levels of excitatory amino
acids are excitotoxic. The primary amino acid responsible appears to be the neurotransmitter glutamate. This review examines the
nature of glutamatergic signaling at the retina and the growing evidence from clinical and animal model studies that glutamate
may be playing similar excitotoxic roles at the diabetic retina.
Copyright © 2007 Jose E. Pulido et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Diabetic retinopathy causes 12,000–24,000 new cases of
blindnesseachyearintheUnitedStatesaloneandisthelead-
ing cause of blindness in persons between the ages of 20–74
[1]. The incidence is increasing as the number of persons
with diabetes mellitus rises. In 2005, it was estimated that
7% of the population in the United States, 20.8 million peo-
ple,haddiabetesmellitus[1].Diabeticretinopathyisamajor
cause of disability with an estimated 40% of adults over the
age of 40 years having some form of diabetic retinopathy and
8% having vision-impairing diabetic retinopathy [2]. The
prevalence of diabetic retinopathy diﬀers with racial charac-
teristics with 50% of adult Hispanics with diabetes mellitus
having some form of diabetic retinopathy [3].
Risk factors for the development of diabetic retinopa-
thy have been well described and can be divided into sys-
temic factors and local factors. The systemic factors include
duration of diabetes, severity of diabetes as measured by
hemoglobin A1c, hypertension, anemia, renal disease, and
lipid levels [4]. The local protective factors include myopia,
the presence of chorioretinal scars, and optic atrophy while
local aggravating factors include inﬂammation and prior is-
chemia [5, 6]. Diabetic retinopathy is caused by an ischemic
microvasculopathyanditisdividedintononproliferativeand
proliferative forms [7]. Both of these forms are presaged on
damage to the capillaries and then the secondary response
to the damage. In the nonproliferative form, there is evi-
dence of leakage from the capillaries as well as drop out of
capillaries. The leakage is manifest as swelling of the retina
and deposition of lipoproteinaceous material in the retina
(hard exudates) as well as microaneurysmal sacculations of
the capillaries and intraretinal hemorrhages [8]. Following
thelossofcapillaries,thereisahypoxicresponsebytheretina
with release of vascular endothelial growth factor (VEGF)
[9]. VEGF is in part what causes leakage from the remaining
capillaries.Itisimportantalsotonotethatthenormalretinal
circulation is under autoregulation [10]. There is a compen-
satory increase or decrease in ﬂow in the retinal circulation
depending upon the physiologic demands from the retina.
This autoregulation may be driven by local nitric oxide pro-
duction[11].Whatdrivestheautoregulationisatthepresent
time speculative but may be intrinsically related to the exci-
tatory amino acids because nitric oxide is associated with ex-
citatory amino acids as will be discussed later [12]. Another
aspect of diabetic retinopathy that is poorly recognized and
occurs because of autoregulation is a compensatory increase
in the ﬂow through the remaining vessels [10].
With ischemia, there is a signiﬁcant release of VEGF,
which causes secondary growth of neovascular tissue on the
surface of the retina. This neovascular tissue is comprised of
very immature vessels that leaks further and bleeds readily.
This is an important cause of visual loss. Ultimately, the ves-
selscauseasecondaryﬁbroticresponseaswellandthiscauses
scarring on the surface of the retina.
Besides VEGF, there may be a panoply of other factors
that may be associated with the changes noted. These factors
may be proteins, peptides, and small molecules [13]. There
is a marked increase in the number of proteins seen in the
vitreous in both experimental as well as in clinical diabetic
retinopathy [13, 14].
T h ev i t r e o u si sa l s oa ﬀected by diabetes and the changed
vitreous is involved in the development of diabetic retinop
athy [15, 16]. The vitreous contracts probably because of2 Experimental Diabetes Research
Table 1: Glutamate Receptors.
Isoforms Glutamate Response
Ionotropic
NMDA NR1, NR2A-D and NR3A-B Increase Ca2+/Na+ intracellular inﬂux
AMPA GluR1, GluR2, GluR3, and GluR4 Increase Na+/(Ca2+) intracellular inﬂux
Kainate GluR5, GluR6, GluR7, KA1, and KA2 Increase Na+/(Ca2+) intracellular inﬂux
Metabotropic
Type I mGluR1, mGluR5 Increase intracellular inositol phosphate and diacylglycerol
Type II mGluR2, mGluR3 Decrease intracellular cyclic adenosine monophosphate
Type III mGluR4, mGluR6, mGluR7, and mGluR8 Modulate intracellular cyclic adenosine monophosphate
nonenzymatic glycosylation [17]. The contraction of the vit-
reous then allows growth of the neovascular tissue onto its
posterior surface and also causes the tissue to bleed.
2. EXCITATORY AMINO ACIDS
Amino acids or their metabolic products have been shown
to be neurotransmitters [18]. Olney was the ﬁrst to recognize
thatagroupoftheseaminoacidswereexcitatory[19,20].He
labelled them as excitatory because the released amino acids
cause rapid depolarization of glutamate sensitive cells. The
number of amino acids that have been designated as excita-
tory has grown since Olney’s initial studies and include glu-
tamate, glycine, aspartate. Glutamate is a critical excitatory
amino acid in the brain and the most important excitatory
amino acid in the retina.
The entries in Table 1 show the types and diversity of
glutamate receptors. There are two classes of glutamate re-
ceptors, ionotropic and metabotropic. The ionotropic re-
ceptors work via ion channels. The metabotropic receptors
are G-protein coupled receptors. There are three subclasses
of ionotropic receptors: N-methyl-D-aspartate (NMDA),
amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA),
and kainate type receptors. The NMDA receptors are the
ones that are most associated with excitatory neurotoxicity
and calciumentry into the cells. The calciumentry causesre-
leaseofcaspasesfromthemitochondria leadingtoapoptosis.
NMDA receptors are made up of 3 diﬀerent subunits, NR1,
NR2A-D, and, in some cases, NR3A or B subunits. The re-
ceptor is probably composed of a tetramer of these subunits.
Alternative splicing further helps in adding pharmacologic
diﬀerences to the action of the receptors. There is a diversity
of NMDA receptor types in diﬀerent regions of the central
nervous system.
There are at least eight metabotropic glutamate recep-
tors (mGluR). These are subdivided into three subclasses.
Type I metabotropic receptors are associated with intracellu-
lar phosphotidyl inositol metabolism. Type II and III recep-
tors are associated with an inhibitory cAMP cascade as well
as other postsynaptic cascades that lead to the release of Ca2+
from intracellular stores. There is some data to suggest that
some of the type II mGluRs are neuroprotective.
There is a relationship between the metabolism of gluta-
mate, glutamine, and GABA. GABA is a synthesized in the
presynatic axons of certain neurons via the use of glutamate
decarboxylase. It is the major inhibitory neurotransmitter in
the brain and retina.
Because of the signiﬁcant neurotoxic eﬀects of gluta-
mate, glutamate concentrations have to be very closely regu-
lated in the synapse. Much of the released glutamate is taken
up by the surrounding glial cells and converted into glu-
tamine. The glutamine is then taken up by the presynaptic
axon. Glutamine is deaminated and turned back into glu-
tamate (Figure 1). Direct glutamate reuptake by the presy-
naptic neuron accounts for a small amount of the released
glutamate. Another small amount actually escapes from the
synaptic space and may have signiﬁcant peripheral eﬀects
[21]. The amount that escapes appears to increase in patho-
logic conditions.
For glutamate, there are ﬁve known high-aﬃnity exci-
tatory amino acid transporters: EAAT1 (GLAST), EAAT2
(GLT-1), EAAT3 (EAAC1), EAAT4, and EAAT5 [22–26]. The
transporters and their predominant locations are shown in
Table 2. Uptake of glutamate into astrocytes is mediated by
GLAST (also found in M¨ uller cells) and GLT1 (or EAAT1
and 2) and into neurons by EAAC1 (or EAAT3), EAAT4, and
EAAT5, of which the last primarily is found in the retinal
photoreceptor cells. In addition, there are glutamine trans-
porters that need to be synchronized to transport glutamine
from the astrocytes into the neurons (Figure 1).
2.1. Excitatoryaminoacidanddiseasestates
Recently, there has been a growing appreciation that disrup-
tion of this cycle leads to glutamate levels that may fall out-
side normal ranges and lead to tissue dysfunction and neu-
ronal death [27]. This process has been implicated in hepatic
failure-associated CNS dysfunction [28], HIV-associated de-
mentia [29], ischemia [30], Alzheimer’s [31], and Hunting-
ton’sdisease[32].Thedetrimentaleﬀectsofexcessglutamate
has largely been related to iontropic receptor overactivation
[27, 30–35]. Treatments that have been proposed and tested
then are aimed at interfering with these receptors though
there is now data that implicates the metobotropic recep-
tors for damage to the postsynaptic cells as well [27, 31–33].
With hepatic failure, there is an increase in ammonia. The
ammonia increase causes a downregulation of GLT1 causing
anaccumulationofextracellularexcitatoryglutamate.Thisis
thought to be one of the leading causes of the CNS derange-
ments seen with hepatic failure [28]. Following ischemic
stroke, there is a marked increase in extracellular glutamate
as well [36]. Both clinical and animal studies have demon-
strated an association between the increase in glutamate lev-
els with worsening neurological deﬁcits. How the increaseJose E. Pulido et al. 3
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Figure 1: Glutamate cycle in the synaptic space.
Table 2: Glutamate Transport Proteins.
Predominant Retinal Localization
Glial EAAT1, GLAST M¨ uller cells and astroglia
EAAT2, GLT1 Bipolar and cone cells
Neuronal
EAAT3, EAAC1 Horizontal, amacrine, ganglion, and bipolar cells
EAAT4
EAAT5 Photoreceptor and bipolar cells
of glutamate occurs, whether it is excessive release, poor re-
uptake or a problem in glutamate-glutamine cycling is still
unknown. Hypoglycemia has also been associated with glu-
tamate neurotoxicity in the central nervous system. Hypo-
glycemia has also been associated with glutamate neurotoxi-
city in the central nervous system [37]. This same neurotoxi-
city has also been reproduced by using iodoacetate which in-
hibits glycolysis. The neurotoxicity induced by hypoglycemia
is inhibited by both glutamate inhibitors as well as pyruvate
presumably by allowing progression of oxidative phosphory-
lation[38].Invivo,potentiationofglutamate-mediatedneu-
ronal damage after chronic administration of the glycolysis
inhibitor iodoacetate [38]. Hyperglycemia has not been as-
sociated with glutamate neurotoxicity in the central nervous
system.
2.2. NMDAantagonists
MK-801 was the ﬁrst NMDA antagonist that was used but
clinically it was associated with coma and delirium. Aman-
tadine, which was originally developed to interfere with
inﬂuenza virus uptake and was then used in patients with
Parkinson’s disease, was noted to have NMDA receptor an-
tagonism. Memantine, a derivative of amantidine, is a more
eﬃcacious NMDA receptor antagonist and has been ap-
proved for the treatment of Alzheimer’s disease and is being
investigated for possible use in other diseases including vas-
cular dementia, neuropathic pain, and glaucoma [27].
2.3. Excitatoryaminoacidsandtheretina
The initial studies by Dreyer showing that glutamate was ele-
vated in glaucoma were subsequently brought into question
[39]. Subsequent studies by ourselves in this issue and others
have shown that glutamate is elevated in the vitreous in glau-
coma, diabetes mellitus, and retinal detachments and thus,
similar to ischemic brain injury, glutamate may play an im-
portant role in these diseases [40–42].
Among the ﬁve excitatory amino acid transporters iden-
tiﬁed to date, four are found in the retina. EAAT1 (GLAST)
is found in M¨ uller cells and astrocytes [43]. EAAT2 (GLT1) is
localized to cones and two types of bipolar cells [44]. EAAT3
(EAAC1) is found on horizontal, amacrine, and ganglion
cells, and occasionally on bipolar cells [45]. EAAT5 is local-
ized to photoreceptors and bipolar cells [46].
Glutamate receptors are present throughout the retina.
The M¨ uller cells in the retina act as the astrocytes in the
brain. They have GLAST expression and are important in
removing glutamate from the synaptic space of the retina
[47]. GLAST1a is also expressed. In this form, exon 3 is not4 Experimental Diabetes Research
expressed which decreases the eﬃcacy of glutamate uptake.
This may be a method of regulating the eﬃcacy of M¨ uller
cell glutamate uptake [48].
Bipolar cells have kainate, AMPA receptors, and NMDA
receptors [21, 49]. For all bipolar cell types, the AMPA re-
ceptor subunits GluR2, 2/3, and 4 are the most common
types while GluR1 are rare. The kainate GluR6/7 are pre-
dominantly associated with diﬀuse bipolar (DB6) and rod
bipolar cells. The NMDA receptor, NR1C2, is seen in ﬂat
midget and DB3 axons. The kainate receptors are seen pri-
marily in dendrites of oﬀ-bipolar cells associated with cone
axons[21].HorizontalreceptorsalsohaveAMPAtyperecep-
tors [50]. On-bipolar cells appear to use metabotropic recep-
tors [51]. In the inner retina, glutamate receptors are present
in the ganglion dendrites and amacrine cells. Metabotropic
type II receptors are present on certain amacrine cells [52].
2.4. Retinaldiseasesassociatedwithelevated
glutamatelevelsinthevitreous
2.4.1. Glaucoma
It has been suggested that increased extracellular glutamate
levels may be due, at least in part, to a failure of glutamate
transporter buﬀering [53]. The data has to be carefully eval-
uated to look at the acute changes and the chronic changes
following injury. For instance, following crush injury to the
optic nerve, there appears to be an acute increase in GLT1
expression followed by a decrease to near normal levels over
time [54].
In a chronic glaucoma model, both ionotropic and
metabotropic antagonists appeared to be eﬀective in lim-
iting damage from glaucoma [55]. The NMDA antago-
nists appeared to have a greater eﬀect in limiting dam-
age than the metabotropic antagonists but this study shows
that metabotropic receptors may be important in glutamate-
induced damage as well. Previous studies using immuno-
histochemistry have demonstrated a reduced expression of
EAAT1 in a rat glaucoma model [56]. It has been shown
in rats that treatment with antisense-oligonucleotides to
GLT-1 leads to increased vitreous glutamate levels and RGC
death [33]. In addition, in human glaucoma the expres-
sion of this glutamate transporter is reduced at the pro-
tein level [57]. Following experimental glaucoma induc-
tion in rats, with subsequent optic nerve damage, Mar-
tin et al. [56] recently found no change in the expres-
sion of GLT1 by immunohistochemistry. However, West-
ern blot analysis revealed a signiﬁcant decrease in the lev-
els of GLT1 protein. Interestingly, following optic nerve
transsection, which leads to extensive RGC death, the GLT1
protein levels were found to be increased in this study
[56].
As mentioned, the relationship between glaucoma and
glutamate has been questioned. In fact, a recent article
showed no relationship between glutatmate levels and glau-
coma in persons with glaucoma requiring vitrectomy [58].
This is diﬀerent from animal models and further human
studies are required.
2.4.2. Retinaldetachmentsanddiabeticretinopathy
In clinical studies, there are mildly elevated levels of gluta-
mate in the vitreous with rhegmatogenous retinal detach-
ments [41] and markedly elevated in cases with diabetic
retinopathy [40] though the number of studies is very lim-
ited and further studies are deﬁnitely warranted to conﬁrm
these ﬁndings. The levels of glutamate in the vitreous of pa-
tients with rhegmatogenous retinal detachment not associ-
ated with diabetic retinopathy was 25% higher than the glu-
tamate levels in the vitreous of patients who underwent vit-
rectomies for other causes [59]. Rhegamtogenous retinal de-
tachments are associated with mild retinal ischemia since
neovascularization is rarely seen with rhegmatogenous reti-
nal detachments and that may be the reason the glutamate
levels were slightly elevated. The cases of diabetic retinopa-
thy that have been associated with elevated glutamate lev-
els were cases with proliferative diabetic retinopathy. In the
study, Ambati and colleagues evaluated levels of glutamate
in eyes with proliferative diabetic retinopathy and compared
the levels to controls who underwent vitrectomies for other
causes. They controlled for hemorrhage in the eyes with pro-
liferative diabetic retinopathy by determining hemoglobin
levels. Even controlling for elevated hemoglobin levels in the
vitreous (as a marker for vitreous hemorrhage), the gluta-
mate levels were at least twice as high as control eyes. Deng
et al. also found elevated vitreous levels of glutamate in cases
of proliferative diabetic retinopathy [60]. In this journal, our
group using capillary electrophoresis, a low volume-sensitive
method reports elevated levels of glutamate as well. On the
contrary, Asensio Sanchez and his coauthors did not ﬁnd el-
evated glutamate levels in the vitreous of patients with dia-
betes in comparison to their control patients [61]. Overall,
there are more studies showing elevation in glutamate levels
with proliferative diabetic retinopathy than studies showing
no diﬀerences but further studies are needed in humans and
if they do show elevations, studies to determine the use of
glutamate inhibitors may then be warranted.
Interestingly, even in animal models of diabetes, the de-
termination of levels of glutamate in the eye is conﬂicting.
In a study by Obrosova et al., that looked at retinas re-
moved from STZ-induced diabetes within 6 weeks follow-
ing induction of diabetes, showed that the levels of gluta-
mate in the retinas were similar to those in the control eyes
for diabetic mice while they were reduced compared to con-
trol eyes for diabetic rats [62]. In this study, they only de-
termined the intraretinal levels and not the vitreous levels.
Ward et al., in a similar animal model showed no diﬀer-
enceinglutamatemetabolismintheretinas[63].Conversely,
other studies have shown that glutamate levels are increased
and it appears that glial cell metabolism is aﬀected [34, 64].
Kerns showed that in their model of alloxan-induced di-
abetic rats, the glutamate levels in the retina were signif-
icantly elevated by 40% compared to control retinas after
two months of hyperglycemia [65]. It may be that compared
to the Obrosova study which did similar intraretinal gluta-
mate sensing, the diﬀerence in comparing to normal after
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study may have been the reason for Kerns ﬁnding a diﬀer-
ence in glutamate levels while Obrosova did not. Lieth et
al. showed that in ex vivo retinas of STZ-induced diabetes
there was reduced glutamate oxidation by 38% compared
to controls. Similarly, Puro used freshly dissected M¨ uller
cells from normal rat eyes and cells from STZ-induced di-
abetes eyes to demonstrate a statistically signiﬁcant diminu-
tion in the glutamate transport in the diabetic group after
four weeks of diabetes. After four weeks of diabetes, a sta-
tistically signiﬁcant diminution could be seen in the gluta-
mate transporter between these two groups. By 13 weeks,
there was a 67% decrease in transporter function compared
to controls. This is similar to other causes of retinal is-
chemia, where the GLAST function in the M¨ uller cells is
markedlydiminished [66]. In addition, neural cellsmay have
altered glutamate receptor function and calcium metabolism
[67].
Besides direct neurotoxic eﬀects, elevated glutamate lev-
els may have other indirect retinotoxic eﬀects as well. We
have previously shown that nitrates are increased in dia-
beticretinopathy[68].Glutamateelevationisassociatedwith
nitric oxide but how it is related is not completely under-
stood. Kerns in his study using rats following 2 month of
hyperglycemia showed that inhibiting glutamate levels de-
creased NO oxide production [65]. Subsequently, no other
studies have been done to evaluate this. Considering that
nitric oxide appears to be an important regulator of reti-
nal vasculature autoregulation, further studies to understand
the relationship between nitric oxide levels and glutamate
are warranted. Finally, there are other pathways that are af-
fected by excitotoxicity. Protein Kinase C (PKC) is activated
by NMDA activation. PKC-ζ inhibitors prevent some of the
damage from NMDA activation but PKC-β inhibitors do
not inhibit neuronal death. PKC-β is activated in diabetes
and appears to be related to diabetic retinopathy but the
relationship between PKC-ζ and diabetes has not been es-
tablished though it is interesting to note that PKC-ζ has
been associated with upregulation of VEGF in other systems
[69, 70].
3. SUMMARY
Thereappearstobearelationshipbetweendiabeticretinopa-
thy and elevated glutamate levels similar to other cases of
CNSischemiaandglaucoma,however,furtherstudiesarere-
quired to conﬁrm this. Though part appears to be an eﬀect
of ischemia on the function of M¨ uller cells, the exact patho-
physiology of how diabetes causes elevated glutamate levels
in thevitreous alsohas to be determined. Whether glutamate
elevation is just a marker disease or actually adds to the com-
plicationsofdiabeteshasnotbeenestablishedbutfromother
diseases that cause elevation of glutamate in the CNS, treat-
ment by glutamate inhibitors appears to decrease neurotoxi-
city. Results of clinical trials of memantine and glaucoma are
ongoing and will help to determine the importance of gluta-
mate in ocular pathologies. How glutamate aﬀects other im-
portant factors, for instance nitric oxide and VEGF, have to
be further elucidated.
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